| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
M1002 (10 μM; 24 h) has the ability to significantly increase HIF-2 target gene expression [1]. Treatment with M1002 (5 μM; 24 hours) demonstrated synergy with inhibitors of the prolyl hydroxylase domain (PHD) [1].
|
|---|---|
| Cell Assay |
RT-PCR[1]
Cell Types: 786-O cells Tested Concentrations: 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control, it has a significant agonistic effect on the expression of HIF-2 target genes in 786-O cells. RT-PCR[1] Cell Types: Hep3B Cell Tested Concentrations: 5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Co-treatment of M1002 with PHD inhibitors increased the expression of EPO and NDRG1 compared to treatment with M1002 alone. |
| References |
| Molecular Formula |
C15H8F6N2O2S
|
|---|---|
| Molecular Weight |
394.2916431427
|
| Exact Mass |
394.021
|
| CAS # |
823830-85-9
|
| PubChem CID |
2220129
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
414.6±55.0 °C at 760 mmHg
|
| Flash Point |
204.6±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.564
|
| LogP |
5.15
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BMTRZTPPTZHACH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H8F6N2O2S/c16-14(17,18)8-5-9(15(19,20)21)7-10(6-8)22-13-11-3-1-2-4-12(11)26(24,25)23-13/h1-7H,(H,22,23)
|
| Chemical Name |
N-[3,5-bis(trifluoromethyl)phenyl]-1,1-dioxo-1,2-benzothiazol-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~126.81 mM)
DMF : 50 mg/mL (~126.81 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5362 mL | 12.6810 mL | 25.3620 mL | |
| 5 mM | 0.5072 mL | 2.5362 mL | 5.0724 mL | |
| 10 mM | 0.2536 mL | 1.2681 mL | 2.5362 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
